Patents by Inventor Timothy B. RHORER

Timothy B. RHORER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17
    Publication number: 20230242537
    Abstract: The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 3, 2023
    Inventors: Steven Goldberg, Connor Martin, Timothy B. Rhorer, Virginia M. Tanis, Xiaohua Xue
  • Imidazopyridazines as modulators of IL-17
    Patent number: 11702422
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: July 18, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Douglas Behenna, Xiaohua Xue, John Keith
  • Imidazopyridazines as modulators of IL-17
    Patent number: 11691979
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: July 4, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, Craig Woods, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Steven Loskot, Douglas Behenna, Alexander Raymond Rovira, Xiaohua Xue
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20230143050
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 11, 2023
    Inventors: Steven D. Goldberg, Dougas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Dongpei Wu, Xiaohua Xue
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20230081548
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 16, 2023
    Inventors: Steven GOLDBERG, Craig WOODS, Timothy B. RHORER, Connor MARTIN, Steven P. MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Xiaohua XUE